STOCK TITAN
  1. Home
  2. News
  3. VAPO

VAPOTHERM INC - $VAPO STOCK NEWS

Welcome to our dedicated page for VAPOTHERM news (Ticker: $VAPO), a resource for investors and traders seeking the latest updates and insights on VAPOTHERM stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VAPOTHERM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VAPOTHERM's position in the market.

News
Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic high flow cannulas
Rhea-AI Summary
Vapotherm announces validation of its high velocity therapy products in treating respiratory distress, with improved CO2 flush compared to other cannulas, benefiting patients with COPD and asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none
-
News
The FDA Approves IDE for ReGelTec’s Pivotal Study of HYDRAFIL® for Chronic Low Back Pain due to Degenerative Disc Disease
Rhea-AI Summary
ReGelTec receives FDA approval for pivotal study on HYDRAFIL System, a treatment for chronic low back pain due to degenerative disc disease. Study to enroll 225 patients in North America, expected to start in early 2024. Early results show 69% reduction in pain scores and 81% improvement in daily living. Company fundraising for study and FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
fda approval
-
News
Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of acute asthma in children
Rhea-AI Summary
Vapotherm presents clinical trial results showing positive outcomes for children with acute severe asthma using HVNI therapy, reducing the need for further escalation of therapy and achieving faster hospital discharge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
none
News
Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing
Rhea-AI Summary
Perimeter Medical Imaging AI, Inc. appoints Adam Hodges as VP of Sales and Marketing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
management AI
-
News
Vapotherm Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Vapotherm, Inc. (NYSE: VAPO) announced second quarter 2023 financial results, reporting a 23.6% increase in net revenue, with gross margin increasing by 780 basis points. The company also saw a decrease in operating expenses and net cash burn, with a net cash balance of $18.0 million. However, the company revised its fiscal 2023 outlook, expecting a decrease in full year revenue, gross margins, and operating expenses compared to previous expectations. Additionally, Vapotherm implemented a 1-for-8 reverse stock split to regain compliance with minimum share price requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
earnings
-
News
Vapotherm To Report Second Quarter 2023 Financial Results
Rhea-AI Summary
Vapotherm, Inc. (NYSE: VAPO) to Release Q2 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
conferences earnings
News
Vapotherm Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
earnings
-
News
Vapotherm To Report First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
conferences earnings
-
News
Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vapotherm Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
earnings
Stock VAPO logo
VAPOTHERM INC

NYSE:VAPO

VAPO Rankings

N/A Ranked by Market Cap
#5333 Ranked by Stock Gains
N/A Ranked by Dividends

VAPO Stock Data

9.91M
2.93M
16.79%
42.95%
7.69%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Exeter

About VAPO

vapotherm develops and manufactures innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. over 1 million patients have been successfully treated with vapotherm hi-vni technology, and the number is growing rapidly every day. we have an unrelenting commitment to improving patient lives, significant sales growth, a dynamic and exciting work environment, and a focus on hiring and developing the very best people in the medical device industry. now is a great time to join our growing team. vapotherm is a privately held company located in exeter, new hampshire. for more information, visit www.vapotherm.com.